Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent is in a strong position with two promising drug candidates in its pipeline, NVL-520 and NVL-330, which target two different types of lung cancer with high market potential. This, combined with Oric’s focus on HER2+ NSCLC, makes for a complementary partnership and sets Nuvalent up for potential growth in the future of the cancer treatment market. Additionally, the positive clinical trial results for zidesamtinib and the low levels of adverse events bode well for its potential success and profitability.

Bears say

Nuvalent is currently a clinical-stage company with no approved products. Despite its promising pipeline targeting cancer-related kinases, the company has yet to see any revenue. Additionally, with larger competitors dominating the market, Nuvalent's projected peak revenues may be optimistic. The company also faces potential challenges to their market exclusivity, which could weaken their competitive position.

Nuvalent (NUVL) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 16 analysts, Nuvalent (NUVL) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.